Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the KORA-Age study

Autor: Uta Ferrari, Canan Selte, Barbara Thorand, Michael Drey, Marietta Rottenkolber, Romy Conzade, Annette Peters, Birgit Linkohr, Cornelia Then, Jochen Seissler
Rok vydání: 2020
Předmět:
Male
medicine.medical_specialty
Sarcopenia
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
Population
030209 endocrinology & metabolism
Timed Up and Go test
Type 2 diabetes
030204 cardiovascular system & hematology
03 medical and health sciences
Grip strength
0302 clinical medicine
Endocrinology
Diabetes
Insulin
Kora-age
Muscle Function
Muscle Mass
Risk Factors
Internal medicine
Diabetes mellitus
Germany
Internal Medicine
medicine
Humans
Longitudinal Studies
Muscle Strength
education
Muscle
Skeletal
Exercise
Geriatric Assessment
Postural Balance
Aged
Aged
80 and over
education.field_of_study
Hand Strength
business.industry
Skeletal muscle
General Medicine
medicine.disease
medicine.anatomical_structure
Diabetes Mellitus
Type 2
Time and Motion Studies
Female
business
Follow-Up Studies
Zdroj: Acta Diabetol. 57, 1057-1063 (2020)
ISSN: 1432-5233
Popis: Aims: The aim of the current study was to investigate the association of type 2 diabetes (T2D) and insulin treatment with changes in muscle mass, muscle strength, and physical performance in older adults. Methods: In 731 participants of the population-based KORA-Age study aged 74.6 ± 6.2years (T2D: n = 118; insulin treatment: n = 20), skeletal muscle index (SMI [kg/m2]), hand grip strength (GS [kg]), and a timed up and go test (TUG [s]) were performed at baseline and after a follow-up time of 3years. The association of T2D and insulin therapy with changes in muscle parameters was analyzed using linear regression models. Results: After adjustment for sex, age, BMI, physical activity, smoking, and multimorbidity, T2D was associated with the change in SMI during follow-up (β − 0.1 (95% CI − 0.3 to − 0.02) kg/m2; p = 0.02), but not with a change in GS (β − 0.9 (95% CI − 1.9 to 0.04) kg) or TUG (β − 0.1 (95% CI − 0.7 to 0.5) s). Insulin therapy was positively associated with change in SMI (β 0.6 (95% CI 0.3–0.9) kg/m2; p = 0.001), but not in GS (β − 1.6 (95% CI − 4.1 to 0.8) kg) or TUG (β 1.6 (95% CI − 0.2–3.4) s) in comparison with treatment with oral anti-diabetic medication alone. Conclusions: Participants with T2D showed an accelerated decline in muscle mass compared to non-diabetic participants. Insulin therapy was associated with preserved muscle mass, but not muscle function parameters, indicating a discrepancy between muscle mass and function in this high-risk population.
Databáze: OpenAIRE
Externí odkaz: